Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy
Elisa Giannetta, Andrea M. Isidori, Nicola Galea, et al.
Circulation (2012) Vol. 125, Iss. 19, pp. 2323-2333
Open Access | Times Cited: 180

Showing 26-50 of 180 citing articles:

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease
Nikolaos Tzoumas, Tariq E. Farrah, Neeraj Dhaun, et al.
British Journal of Pharmacology (2019) Vol. 177, Iss. 24, pp. 5467-5488
Open Access | Times Cited: 94
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
David Hutchings, Simon Anderson, Jessica L. Caldwell, et al.
Heart (2018) Vol. 104, Iss. 15, pp. 1244-1250
Open Access | Times Cited: 84
Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders
Arun Samidurai, Lei Xi, Anindita Das, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 585-615
Open Access | Times Cited: 64
Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity
Xin Zhang, Can Hu, Yuan Xiao-pin, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 7
Open Access | Times Cited: 61
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
Rima Kamel, Jérôme Leroy, Grégoire Vandecasteele, et al.
Nature Reviews Cardiology (2022) Vol. 20, Iss. 2, pp. 90-108
Closed Access | Times Cited: 51
Diabetic cardiomyopathy: Clinical phenotype and practice
Xudong Zhao, Shengwang Liu, Xiao Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 46
Diabetic Cardiomyopathy—From Basics through Diagnosis to Treatment
Ewa Radzioch, Bartłomiej Dąbek, Marta Balcerczyk-Lis, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 765-765
Open Access | Times Cited: 8
Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status
Andrea Sansone, Eugenia Guida, Susanna Dolci, et al.
Basic and Clinical Andrology (2025) Vol. 35, Iss. 1
Open Access | Times Cited: 1
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors
Roberto Bruzziches, Davide Francomano, Pietro Gareri, et al.
Expert Opinion on Pharmacotherapy (2013) Vol. 14, Iss. 10, pp. 1333-1344
Closed Access | Times Cited: 97
THERAPY OF ENDOCRINE DISEASE: Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis
Daniele Santi, Elisa Giannetta, Andrea M. Isidori, et al.
European Journal of Endocrinology (2014) Vol. 172, Iss. 3, pp. R103-R114
Open Access | Times Cited: 88
Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling
Saisudha Koka, Hema Aluri, Lei Xi, et al.
AJP Heart and Circulatory Physiology (2014) Vol. 306, Iss. 11, pp. H1558-H1568
Open Access | Times Cited: 86
Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase‐5A inhibitor vardenafil in rats with type 2 diabetes
Csaba Mátyás, Balázs Tamás Németh, Attila Oláh, et al.
European Journal of Heart Failure (2016) Vol. 19, Iss. 3, pp. 326-336
Open Access | Times Cited: 85
Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials
Elisa Giannetta, Tiziana Feola, Daniele Gianfrilli, et al.
BMC Medicine (2014) Vol. 12, Iss. 1
Open Access | Times Cited: 84
Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy
Doris Leung, Daniel A. Herzka, William Thompson, et al.
Annals of Neurology (2014) Vol. 76, Iss. 4, pp. 541-549
Open Access | Times Cited: 81
Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1
A Hopf, Christian Andresen, Sebastian Kötter, et al.
Circulation Research (2018) Vol. 123, Iss. 3, pp. 342-355
Open Access | Times Cited: 80
Targeting Cardiac Hypertrophy
Egbert Bisping, Paulina Wakula, Michael Poteser, et al.
Journal of Cardiovascular Pharmacology (2014) Vol. 64, Iss. 4, pp. 293-305
Closed Access | Times Cited: 71
The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study
Adbul Larghat, Peter Swoboda, John Biglands, et al.
European Heart Journal - Cardiovascular Imaging (2014) Vol. 15, Iss. 12, pp. 1368-1376
Open Access | Times Cited: 71
Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes
Andrea M. Isidori, Mary Anna Venneri, Daniela Fiore
Journal of Endocrinological Investigation (2016) Vol. 39, Iss. 11, pp. 1235-1246
Closed Access | Times Cited: 69
Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
Grace Kim, David A. Kass
Handbook of experimental pharmacology (2016), pp. 249-269
Open Access | Times Cited: 67
Targeting the NO‐cGMP‐PDE5 pathway in COVID‐19 infection. The DEDALO project
Andrea M. Isidori, Elisa Giannetta, Riccardo Pofi, et al.
Andrology (2020) Vol. 9, Iss. 1, pp. 33-38
Open Access | Times Cited: 57
Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial
Riccardo Pofi, Elisa Giannetta, Tiziana Feola, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 649
Closed Access | Times Cited: 36
Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study
Shuyi Li, Si Chen, Xiaoting Lu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 29
Phosphodiesterase in heart and vessels: from physiology to diseases
Qin Fu, Ying Wang, Chen Yan, et al.
Physiological Reviews (2023) Vol. 104, Iss. 2, pp. 765-834
Open Access | Times Cited: 18
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo
Dirk Westermann, Peter Moritz Becher, Diana Lindner, et al.
Basic Research in Cardiology (2012) Vol. 107, Iss. 6
Closed Access | Times Cited: 73
Investigational drugs targeting cardiac fibrosis
François Roubille, David Busseuil, Nolwenn Merlet, et al.
Expert Review of Cardiovascular Therapy (2013) Vol. 12, Iss. 1, pp. 111-125
Closed Access | Times Cited: 60

Scroll to top